N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Launched by BETH ISRAEL DEACONESS MEDICAL CENTER · May 13, 2011
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
The study proposes that a glutathione deficit leading to an abnormal response to oxidative stress is a vulnerability factor, combined with other brain specific factors, in brain functioning of some individuals with schizophrenia (Do et al., 2010). N-acetyl-cysteine is hypothesized to cross the blood-brain barrier and increase glutathione in the brain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Capacity to provide informed consent
- • DSM IV TR diagnosis of schizophrenia, schizophreniform, schizoaffective
- • Psychiatric and medical stability
- • Prescribing clinician's premission to participate, assurance of medical stability
- • Having met threshold criteria for psychosis on CAARMS (Comprehensive Assessment of at Risk Mental States Scale) Psychosis subscale
- • Up to 12 months of antipsychotic treatment
- Exclusion Criteria:
- • Severe medical comorbidities
- • Previous cerebral trauma
- • Substance induced psychosis or organic psychosis
- • Mental retardation
- • NAC allergy
- • Pregnancy, females and males planning pregnancy
- • Treatment with antioxidants
- • Insufficient command of English
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center (BIDMC) is a leading academic medical center located in Boston, Massachusetts, affiliated with Harvard Medical School. Renowned for its commitment to cutting-edge research and innovation in healthcare, BIDMC fosters a collaborative environment that integrates patient care, education, and scientific investigation. The center actively sponsors clinical trials across a variety of disciplines, aiming to advance medical knowledge and improve patient outcomes. With a focus on translational medicine, BIDMC's research initiatives engage multidisciplinary teams to address complex health challenges and translate findings into effective therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Ann Cousins, PhD, APRN
Study Director
Beth Israel Deaconess Medical Center
T. U. Wilson Woo, MD, PhD
Study Chair
Harvard Medical School (HMS and HSDM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials